Scott S Zamvil - University of California

Scott S Zamvil

University of California

United States

ORCID logohttps://orcid.org/0000-0003-2720-9915

Scott S Zamvil - University of California

Scott S Zamvil

Introduction

Primary Affiliation: University of California - United States

Publications

101Publications

1696Reads

2Profile Views

2077PubMed Central Citations

The Evolving Mechanisms of Action of Glatiramer Acetate.

Cold Spring Harb Perspect Med 2019 Feb 1;9(2). Epub 2019 Feb 1.

Department of Neurology and Program in Immunology, University of California, San Francisco, San Francisco, California 94158.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1101/cshperspect.a029249DOI Listing
February 2019
7.560 Impact Factor

A young man with numbness in arms and legs: From the National Multiple Sclerosis Society Case Conference Proceedings.

Neurol Neuroimmunol Neuroinflamm 2018 Nov 23;5(6):e509. Epub 2018 Oct 23.

Department of Neurology (A.R.R., S.S.Z., J.M.G.) and Program in Immunology (S.S.Z.), University of California San Francisco; Department of Neurology (R.P.L.), Wayne State University, Detroit, MI; Partner's Neurology Training Program (E.M.); MGH and Brigham and Women's Hospitals, Harvard Medical School, Boston, MA; and E.M. is now with the Department of Neurology, Dell Medical School at the University of Texas at Austin; Central Texas Neurology Consultants (E.J.F.), and Department of Neurology, Dell Medical School at the University of Texas at Austin; Department of Neurology (E.M., A.L.), and Department of Neurology and Ophthalmology (T.C.F., E.F), Dell Medical School at the University of Texas at Austin; Department of Neurology (L.F.), University of Texas at Houston; and the National Multiple Sclerosis Society, New York, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000509DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6225923PMC
November 2018

T cells take aim at a ubiquitous autoantigen in multiple sclerosis.

Sci Transl Med 2018 10;10(462)

Multiple Sclerosis Center, Department of Neurology and Program in Immunology, University of California, San Francisco, San Francisco, CA 94107, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1126/scitranslmed.aau8826DOI Listing
October 2018
15.843 Impact Factor

Functional characterization of reappearing B cells after anti-CD20 treatment of CNS autoimmune disease.

Proc Natl Acad Sci U S A 2018 09 7;115(39):9773-9778. Epub 2018 Sep 7.

Institute of Neuropathology, University Medical Center, 37099 Göttingen, Germany;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1810470115DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6166805PMC
September 2018
4 Reads
9.810 Impact Factor

Vascular niche IL-6 induces alternative macrophage activation in glioblastoma through HIF-2α.

Nat Commun 2018 02 8;9(1):559. Epub 2018 Feb 8.

Department of Radiation Oncology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41467-018-03050-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5805734PMC
February 2018
20 Reads
10.742 Impact Factor

Induction of Paralysis and Visual System Injury in Mice by T Cells Specific for Neuromyelitis Optica Autoantigen Aquaporin-4.

J Vis Exp 2017 08 21(126). Epub 2017 Aug 21.

Department of Neurology, University of California; Program in Immunology, University of California;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3791/56185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5614352PMC
August 2017
51 Reads
2 Citations

Aryl hydrocarbon receptor activity may serve as a surrogate marker for MS disease activity.

Neurol Neuroimmunol Neuroinflamm 2017 Jul 16;4(4):e366. Epub 2017 Jun 16.

Multiple Sclerosis Center, Department of Neurology, University of California San Francisco.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000366DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5473954PMC
July 2017
3 Reads
1 Citation

Acute liver injury in a Glatopa-treated patient with MS.

Neurol Neuroimmunol Neuroinflamm 2017 Jul 5;4(4):e368. Epub 2017 Jun 5.

Multiple Sclerosis Center (J.J.S., S.S.Z., B.A.C.C.), Department of Neurology, Division of Gastroenterology (N.J.M.), Department of Medicine, and GI-Hepatobiliary Pathology Service (S.K.), Department of Pathology, University of California San Francisco.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000368DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459788PMC
July 2017
37 Reads

T cells targeting neuromyelitis optica autoantigen aquaporin-4 cause paralysis and visual system injury.

J Nat Sci 2017 May;3(5)

Department of Neurology, University of California, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5523104PMC
May 2017
20 Reads

Restoring immune tolerance in neuromyelitis optica: Part I.

Neurol Neuroimmunol Neuroinflamm 2016 Oct 7;3(5):e276. Epub 2016 Sep 7.

Department of Neurology (L.S.), Stanford University School of Medicine, Palo Alto, CA; Neuroimmunology Unit and Experimental Therapeutics Program (A.B.-O.), Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada; The Guthy-Jackson Charitable Foundation (J.M.B.), San Diego, CA; Department of Gastroenterology (D.B.-R., P.V.), Hospital Clínic, CIBERehd and Center of Neuroimmunology & Inflammatory Bowel Disease, Institut d'Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Barcelona, Spain; Genentech, Inc. (P.S.C.), South San Francisco, CA; Department of Pathology (M.C.-S.), University of Florida School of Medicine, Gainesville; Opexa Therapeutics (D.H.), The Woodlands, TX; Department of Surgery (J.I.K.), Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Department of Biochemistry (D.M.K.), University of Illinois, Urbana; Neuroimmunology and MS Research (A.L., R.M., S.S.), Department of Neurology, University Hospital Zurich, University Zurich, Switzerland; Forest Landing Court (H.L.W.), Rockville, MD; Ann Romney Center for Neurologic Diseases (S.S.Z.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Neurology and Program in Immunology (H.L.W.), University of California, San Francisco School of Medicine; Department of Medicine (S.S.Z.), Divisions of Molecular Medicine & Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles; Harbor-UCLA Medical Center & LABioMed at Harbor-UCLA Medical Center (M.R.Y.), Torrance, CA; Department of Ophthalmology and Visual Sciences, Kellogg Eye Center, and Division of Metabolism and Endocrine Diseases, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor (T.J.S.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000276DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015539PMC
October 2016
49 Reads
5 Citations

Restoring immune tolerance in neuromyelitis optica: Part II.

Neurol Neuroimmunol Neuroinflamm 2016 Oct 7;3(5):e277. Epub 2016 Sep 7.

Neuroimmunology Unit and Experimental Therapeutics Program (A.B.-O.), Montreal Neurological Institute and Hospital, McGill University, Montreal, Canada; Department of Neurology (L.S.), Stanford University School of Medicine, Palo Alto; The Guthy-Jackson Charitable Foundation (J.M.B.), San Diego, CA; Department of Gastroenterology (D.B.-R., P.V.), Hospital Clínic, CIBERehd and Center of Neuroimmunology & Inflammatory Bowel Disease, Institut d'Investigacions Biomèdiques August Pi Sunyer, Barcelona, Spain; Genentech, Inc. (P.S.C.), South San Francisco, CA; Department of Pathology (M.C.-S.), University of Florida School of Medicine, Gainesville; Opexa Therapeutics (D.H.), The Woodlands, TX; Department of Surgery (J.I.K.), Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA; Department of Biochemistry (D.M.K.), University of Illinois, Urbana; Neuroimmunology and MS Research (A.L., R.M., S.S.), Department of Neurology, University Hospital Zurich, University Zurich, Switzerland; Ann Romney Center for Neurologic Diseases (H.L.W.), Department of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Department of Neurology and Program in Immunology (S.S.Z.), University of California, San Francisco School of Medicine; Department of Ophthalmology and Visual Sciences (T.J.S.), Kellogg Eye Center, and Division of Metabolism, Endocrine and Diabetes, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor; Department of Medicine (M.R.Y.), Divisions of Molecular Medicine & Infectious Diseases, David Geffen School of Medicine at UCLA, Los Angeles; and Harbor-UCLA Medical Center & LABioMed at Harbor-UCLA Medical Center (M.R.Y.), Torrance, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000277DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5015540PMC
October 2016
46 Reads
4 Citations

Treatment of spontaneous EAE by laquinimod reduces Tfh, B cell aggregates, and disease progression.

Neurol Neuroimmunol Neuroinflamm 2016 Oct 21;3(5):e272. Epub 2016 Sep 21.

Department of Neurology (M.V.-D., K.L.P., C.M.S., B.A.C.C., U.S.-T., S.S.Z.) and Program in Immunology (M.V.-D., K.L.P., C.M.S., U.S.-T., S.S.Z.), University of California, San Francisco; Multiple Sclerosis Research Group (C.C.A.B.), Australian Regenerative Medicine Institute, Monash University, Clayton, Australia; and Department of Pathology (R.A.S.), Stanford University, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000272DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5032667PMC
October 2016
20 Reads
5 Citations

Gut microbiome analysis in neuromyelitis optica reveals overabundance of Clostridium perfringens.

Ann Neurol 2016 09 4;80(3):443-7. Epub 2016 Aug 4.

Department of Neurology, University of California, San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.24718DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053302PMC
September 2016
1 Read
13 Citations
9.980 Impact Factor

Your nose knows how to target brain inflammation.

Brain 2016 07;139(Pt 7):1866-9

Department of Neurology and Program in Immunology, University of California, San Francisco, San Francisco, CA, USA

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/brain/aww121DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4939693PMC
July 2016
1 Read
9.200 Impact Factor

Antibodies in multiple sclerosis oligoclonal bands target debris.

Proc Natl Acad Sci U S A 2016 07 28;113(28):7696-8. Epub 2016 Jun 28.

Department of Neurology, University of California, San Francisco, CA 94143; Immunology Program, University of California, San Francisco, CA 94143

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1609246113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4948325PMC
July 2016
1 Read
2 Citations
9.810 Impact Factor

Beginning of the end of two-stage theory purporting that inflammation then degeneration explains pathogenesis of progressive multiple sclerosis.

Curr Opin Neurol 2016 06;29(3):340-4

aDepartment of Neurology and Neurologic Sciences, Interdepartmental Program in Immunology, Stanford University, Stanford bDepartment of Neurology and Program in Immunology, University of California, San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/co-neurology/2016/06000/Beginni
Web Search
http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:land
Publisher Site
http://dx.doi.org/10.1097/WCO.0000000000000317DOI Listing
June 2016
10 Reads
7 Citations
5.310 Impact Factor

Dimethyl fumarate treatment induces adaptive and innate immune modulation independent of Nrf2.

Proc Natl Acad Sci U S A 2016 Apr 13;113(17):4777-82. Epub 2016 Apr 13.

Department of Neurology, University of California, San Francisco, CA 94143; Program in Immunology, University of California, San Francisco, CA 94143;

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.1603907113DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4855599PMC
April 2016
37 Reads
34 Citations
9.810 Impact Factor

Update on the autoimmune pathology of multiple sclerosis: B-cells as disease-drivers and therapeutic targets.

Eur Neurol 2015 25;73(3-4):238-46. Epub 2015 Mar 25.

Department of Neurology, University of California San Francisco, San Francisco, Calif., USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000377675DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4401636PMC
April 2016
3 Reads
7 Citations
1.362 Impact Factor

CNS accumulation of regulatory B cells is VLA-4-dependent.

Neurol Neuroimmunol Neuroinflamm 2016 Apr 9;3(2):e212. Epub 2016 Mar 9.

Department of Neurology and Program in Immunology (K.L.-H., S.A.S., R.C.W., C.M.S., S.S.Z.), University of California, San Francisco; Multiple Sclerosis Research Group (C.C.A.B.), Australian Regenerative Medicine Institute, Monash University, Clayton, Australia; and Department of Pathology (R.A.S.), Stanford University School of Medicine, CA. Dr. Lehmann-Horn is currently with the Department of Neurology, Klinikum rechts der Isar, Technische Universität München; Munich Cluster for Systems Neurology (SyNergy), Munich, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000212DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794810PMC
April 2016
23 Reads
5 Citations

Glatiramer acetate treatment negatively regulates type I interferon signaling.

Neurol Neuroimmunol Neuroinflamm 2015 Dec 9;2(6):e179. Epub 2015 Nov 9.

Department of Neurology and Program in Immunology (N.M., T.P., U.S.-T., C.M.S., J.C.P., S.S.Z.), University of California, San Francisco; the Institute of Neuropathology and Department of Neurology (M.S.W.), University Medical Center, Georg-August University, Göttingen, Germany; the Department of Pathology and Immunology (P.H.L.), Faculty of Medicine, University of Geneva; and the Department of Neurosciences (P.H.L.), Division of Neurology, University Hospital of Geneva, Switzerland. N.M. is currently affiliated with the Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, and Department of Neurosciences, Division of Neurology, University Hospital of Geneva, Switzerland. T.P. is currently affiliated with Momenta Pharmaceuticals, Cambridge, MA. U.S.-T. is currently affiliated with Silence Therapeutics GmbH, Berlin, Germany. J.C.P. is currently affiliated with Vedanta Biosciences, Inc., Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000179DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645172PMC
December 2015
26 Reads
2 Citations

Unique invariant CD8(+) T cell population persists in MS.

Neurol Neuroimmunol Neuroinflamm 2015 Aug 27;2(4):e140. Epub 2015 Jul 27.

Department of Neurology (J.J.S.), Johns Hopkins Hospital, Baltimore, MD; and Department of Neurology (S.S.Z.), University of California, San Francisco.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000140DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4529280PMC
August 2015
4 Reads

B lymphocytes in neuromyelitis optica.

Neurol Neuroimmunol Neuroinflamm 2015 Jun 7;2(3):e104. Epub 2015 May 7.

Departments of Neurology and Ophthalmology and Neuroscience Program (J.L.B.), University of Colorado, Denver; Department of Neurology (K.C.O.), Yale University School of Medicine, New Haven, CT; Neuroimmunology Unit (A.B.-O.), Montreal Neurological Institute and Hospital, McGill University, Montreal, Quebec, Canada; Department of Neurology (S.S.Z., H.-C.v.B.), UCSF School of Medicine, San Francisco, CA; Department of Neurology (B.H.), Technische Universität München, Munich Cluster for Systems Neurology (SyNergy), Munich, Germany; Department of Immunology (T.F.T.), Duke University Medical Center, Durham, NC; Departments of Neurology and Neurotherapeutics (O.S.), University of Texas Southwestern Medical Center, Dallas, TX; Department of Medicine (M.R.Y.), Divisions of Molecular Medicine and Infectious Diseases, University of California, Los Angeles; Harbor-UCLA Medical Center (M.R.Y.), Torrance, CA; Departments of Ophthalmology and Visual Sciences and Internal Medicine (T.J.S.), University of Michigan Medical School, Ann Arbor; and Institute of Neuropathology (C.S.), University Medical Center, Göttingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4426682PMC
June 2015
49 Reads
20 Citations

Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate.

Neurol Neuroimmunol Neuroinflamm 2015 Jun 12;2(3):e76. Epub 2015 Feb 12.

Department of Neurology, University of California, San Francisco.

View Article

Download full-text PDF

Source
http://nn.neurology.org/lookup/doi/10.1212/NXI.0000000000000
Publisher Site
http://dx.doi.org/10.1212/NXI.0000000000000076DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335821PMC
June 2015
16 Reads
37 Citations

B-cell very late antigen-4 deficiency reduces leukocyte recruitment and susceptibility to central nervous system autoimmunity.

Ann Neurol 2015 May 28;77(5):902-8. Epub 2015 Mar 28.

Department of Neurology, University of California; Program in Immunology, University of California, San Francisco, San Francisco, CA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.24387DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4405474PMC
May 2015
6 Reads
13 Citations
9.980 Impact Factor

Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder?

Neurol Neuroimmunol Neuroinflamm 2015 Feb 22;2(1):e62. Epub 2015 Jan 22.

Department of Neurology and Program in Immunology (S.S.Z.), University of California, San Francisco; and Abbvie Bioresearch Center Inc. (A.J.S.), Worcester, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000062DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4309526PMC
February 2015
15 Reads
58 Citations

Laquinimod, an up-and-coming immunomodulatory agent for treatment of multiple sclerosis.

Exp Neurol 2014 Dec 13;262 Pt A:66-71. Epub 2014 Apr 13.

Department of Neurology, University of California, San Francisco, CA 94158, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.expneurol.2014.04.002DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195809PMC
December 2014
4 Reads
7 Citations
4.700 Impact Factor

Immunodominant T-cell epitopes of MOG reside in its transmembrane and cytoplasmic domains in EAE.

Neurol Neuroimmunol Neuroinflamm 2014 Aug 14;1(2):e22. Epub 2014 Aug 14.

Department of Neurology and Program in Immunology (A.S., S.G.G., M.V.-D., T.P., N.M., P.A.N., J.C.P., U.S.-T., S.S.Z.), University of California, San Francisco; Department of Neuropathology and Department of Neurology (M.S.W.), University Medical Center, Georg-August University, Göttingen, Germany; Department of Immunology (N.J., T.F.), University of Texas at San Antonio; Boehringer Ingelheim (S.E.F., A.J.S.), Ridgefield, CT; Department of Pathology (R.A.S.), Stanford University, Stanford, CA; and Multiple Sclerosis Research Group (C.C.A.B.), Australian Regenerative Medicine Institute, Monash University, Clayton, Victoria, Australia. S.G.G. is currently at the Institute for Immunity Transplantation and Infection, Stanford University, Stanford, CA. T.P. is currently at Momenta Pharmaceuticals, Cambridge, MA. N.M. is currently at the Division of Neurology, Department of Clinical Neurosciences, Geneva University Hospital and the Department of Pathology and Immunology, Geneva Faculty of Medicine, University Medical Center, Geneva, Switzerland. J.C.P. is currently at Pfizer, Inc., Cambridge, MA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000022DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202928PMC
August 2014
30 Reads
14 Citations

MOG transmembrane and cytoplasmic domains contain highly stimulatory T-cell epitopes in MS.

Neurol Neuroimmunol Neuroinflamm 2014 Aug 14;1(2):e20. Epub 2014 Aug 14.

Department of Neurology and Program in Immunology (M.V.-D., A.S., C.M.S., U.S.-T., B.A.C.C., S.S.Z.), University of California, San Francisco; Department of Neuropathology and Department of Neurology (M.S.W.), University Medical Center, Georg-August University, Göttingen, Germany; Multiple Sclerosis Research Group (C.C.A.B.), Australian Regenerative Medicine Institute, Monash University, Clayton, Victoria, Australia; Department of Immunology (T.F.), University of Texas at San Antonio; and Boehringer Ingelheim (A.J.S.), Ridgefield, CT.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/NXI.0000000000000020DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4202926PMC
August 2014
30 Reads
7 Citations

Neither T-helper type 2 nor Foxp3+ regulatory T cells are necessary for therapeutic benefit of atorvastatin in treatment of central nervous system autoimmunity.

J Neuroinflammation 2014 Feb 6;11:29. Epub 2014 Feb 6.

Department of Neurology, University of California, 675 Nelson Rising Lane NS-215A, San Francisco, CA 94158, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1742-2094-11-29DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922392PMC
February 2014
28 Reads
8 Citations
5.410 Impact Factor

Tob1 plays a critical role in the activation of encephalitogenic T cells in CNS autoimmunity.

J Exp Med 2013 Jul;210(7):1301-9

Department of Neurology, University of California, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20121611DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3698524PMC
July 2013
23 Reads
13 Citations
12.520 Impact Factor

The neonatal CNS is not conducive for encephalitogenic Th1 T cells and B cells during experimental autoimmune encephalomyelitis.

J Neuroinflammation 2013 May 24;10:67. Epub 2013 May 24.

Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390-9036, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/1742-2094-10-67DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3679999PMC
May 2013
33 Reads
6 Citations
5.410 Impact Factor

Laquinimod, a quinoline-3-carboxamide, induces type II myeloid cells that modulate central nervous system autoimmunity.

PLoS One 2012 30;7(3):e33797. Epub 2012 Mar 30.

Department of Neurology and Program in Immunology, University of California, San Francisco, San Francisco, California, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0033797PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3316495PMC
November 2012
23 Reads
32 Citations
3.234 Impact Factor

K+ channel alterations in the progression of experimental autoimmune encephalomyelitis.

Neurobiol Dis 2012 Aug 24;47(2):280-93. Epub 2012 Apr 24.

Integrated Biomedical Graduate Program, The Ohio State University, Columbus, OH 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nbd.2012.04.012DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3367054PMC
August 2012
5 Reads
10 Citations
5.080 Impact Factor

Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter.

Ann Neurol 2012 Jul 17;72(1):53-64. Epub 2012 Jul 17.

Departments of Neurology, University of California at San Francisco, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.23651DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3405197PMC
July 2012
2 Reads
68 Citations
9.980 Impact Factor

Laquinimod, a once-daily oral drug in development for the treatment of relapsing-remitting multiple sclerosis.

Expert Rev Clin Pharmacol 2012 May;5(3):245-56

Department of Neuropathology, University Medical Center Göttingen, Robert Koch Street 40, 37075 Göttingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/ecp.12.12DOI Listing
May 2012
28 Reads
10 Citations

Re-engineering of pathogenic aquaporin 4-specific antibodies as molecular decoys to treat neuromyelitis optica.

Ann Neurol 2012 Mar;71(3):287-8

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.23538DOI Listing
March 2012
2 Citations
9.980 Impact Factor

B cells in multiple sclerosis: connecting the dots.

Curr Opin Immunol 2011 Dec 7;23(6):713-20. Epub 2011 Oct 7.

Department of Neurology, University of California San Francisco, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.coi.2011.09.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188435PMC
December 2011
3 Reads
28 Citations
7.480 Impact Factor

Accelerated central nervous system autoimmunity in BAFF-receptor-deficient mice.

J Neurol Sci 2011 Jul 6;306(1-2):9-15. Epub 2011 May 6.

Department of Neurology and Neuroscience Graduate Program, University of California Davis, Davis, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jns.2011.04.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172440PMC
July 2011
2 Reads
6 Citations
2.474 Impact Factor

Glatiramer acetate in the treatment of multiple sclerosis: emerging concepts regarding its mechanism of action.

CNS Drugs 2011 May;25(5):401-14

Department of Neurosciences, Geneva University Hospital and University of Geneva, Geneva, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/11588120-000000000-00000DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3963480PMC
May 2011
27 Reads
35 Citations
5.113 Impact Factor

Proinflammatory role of aquaporin-4 in autoimmune neuroinflammation.

FASEB J 2011 May 21;25(5):1556-66. Epub 2011 Jan 21.

Department of Medicine, University of California, San Francisco, California 94143-0521, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1096/fj.10-177279DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3079299PMC
May 2011
1 Read
49 Citations
5.043 Impact Factor

Switching multiple sclerosis patients with breakthrough disease to second-line therapy.

PLoS One 2011 Feb 3;6(2):e16664. Epub 2011 Feb 3.

Multiple Sclerosis Center, Department of Neurology, University of California San Francisco, San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0016664PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3033401PMC
February 2011
24 Reads
18 Citations
3.234 Impact Factor

Translational research in neurology and neuroscience 2010: multiple sclerosis.

Arch Neurol 2010 Nov 12;67(11):1307-15. Epub 2010 Jul 12.

Neurology Section, VA North Texas Health Care System, Medical Service, 4500 S Lancaster Rd, Dallas, TX 75216, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/archneurol.2010.158DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3670826PMC
November 2010
25 Reads
5 Citations
7.420 Impact Factor

Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica.

PLoS One 2010 Nov 30;5(11):e15050. Epub 2010 Nov 30.

Department of Neurology, University of California San Francisco, San Francisco, California, United States of America.

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0015050PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2994828PMC
November 2010
26 Reads
23 Citations
3.234 Impact Factor

FTY720 and central memory: out of sight, out of mind.

Neurology 2010 Aug 7;75(5):388-9. Epub 2010 Jul 7.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/WNL.0b013e3181eee298DOI Listing
August 2010
13 Reads
1 Citation
8.290 Impact Factor

Depletion of B lymphocytes from cerebral perivascular spaces by rituximab.

Arch Neurol 2009 Aug;66(8):1016-20

Department of Neurology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/archneurol.2009.157DOI Listing
August 2009
27 Reads
25 Citations
7.420 Impact Factor

Glatiramer acetate increases IL-1 receptor antagonist but decreases T cell-induced IL-1beta in human monocytes and multiple sclerosis.

Proc Natl Acad Sci U S A 2009 Mar 2;106(11):4355-9. Epub 2009 Mar 2.

Division of Immunology and Allergy, Clinical Immunology Unit (Hans Wilsdorf Laboratory), Department of Internal Medicine, University Hospital and Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1073/pnas.0812183106DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2649955PMC
March 2009
12 Reads
49 Citations
9.810 Impact Factor

Disease-modifying agents for multiple sclerosis: recent advances and future prospects.

Drugs 2008 ;68(17):2445-68

Department of Neurology, Heinrich Heine-University, Düsseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/0003495-200868170-00004DOI Listing
February 2009
1 Read
18 Citations
4.343 Impact Factor

Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.

Arch Neurol 2008 Dec 13;65(12):1596-603. Epub 2008 Oct 13.

Department of Neurology, University of Texas Southwestern Medical Center at Dallas, Neurology Section, Veterans Affairs North Texas Health Care System, Medical Service, 4500 S Lancaster Rd, Dallas, TX 75216, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/archneur.65.12.noc80051DOI Listing
December 2008
25 Reads
39 Citations
7.420 Impact Factor

Glatiramer acetate treatment does not modify the clinical course of (NZB x BXSB)F1 lupus murine model.

Int Immunol 2008 Oct 6;20(10):1313-9. Epub 2008 Aug 6.

Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva , Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/intimm/dxn086DOI Listing
October 2008
11 Reads
4 Citations
2.540 Impact Factor

Bench to bedside: tempering antigen-presenting cells in multiple sclerosis.

Nat Med 2008 Jun;14(6):614-5

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm0608-614DOI Listing
June 2008
3 Reads
5 Citations
27.363 Impact Factor

Pharmacological treatment of early multiple sclerosis.

Drugs 2008 ;68(1):73-83

Neurology Section, VA North Texas Health Care System, Medical Service, Dallas, Texas 75216, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00003495-200868010-00005DOI Listing
February 2008
7 Reads
6 Citations
4.343 Impact Factor

The immunogenicity of disease-modifying therapies for multiple sclerosis: clinical implications for neurologists.

Neurologist 2007 Nov;13(6):355-62

University of Texas Medical Branch, MS Clinic of Central Texas, Round Rock, Texas 78681, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/NRL.0b013e318148c08eDOI Listing
November 2007
1 Read
4 Citations
1.080 Impact Factor

Mechanism of action of glatiramer acetate in treatment of multiple sclerosis.

Neurotherapeutics 2007 Oct;4(4):647-53

Department of Neurology and Program in Immunology, University of California, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nurt.2007.08.002DOI Listing
October 2007
1 Read
22 Citations

Statins--treatment option for central nervous system autoimmune disease?

Neurotherapeutics 2007 Oct;4(4):693-700

Department of Neurology and Program in Immunology, University of California, San Francisco, California 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nurt.2007.08.004DOI Listing
October 2007
27 Reads
5 Citations

Neuroimmunotherapeutics comes of age.

Neurotherapeutics 2007 Oct;4(4):569-70

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.nurt.2007.08.006DOI Listing
October 2007
3 Reads
1 Citation

Type II monocytes modulate T cell-mediated central nervous system autoimmune disease.

Nat Med 2007 Aug 5;13(8):935-43. Epub 2007 Aug 5.

Department of Neurology and Program in Immunology, University of California, San Francisco, 513 Parnassus Avenue, S-268, San Francisco, California 94143-0435, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm1620DOI Listing
August 2007
27 Reads
139 Citations
27.363 Impact Factor

Combination therapies for multiple sclerosis: scientific rationale, clinical trials, and clinical practice.

Curr Opin Neurol 2007 Jun;20(3):281-5

Departments of Medicine, The University of Ottawa, Ottawa, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/WCO.0b013e328122de1bDOI Listing
June 2007
5 Reads
6 Citations
5.310 Impact Factor

T effectors outfox T regulators in autoimmunity.

Nat Med 2007 Apr;13(4):411-3

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm0407-411DOI Listing
April 2007
2 Reads
3 Citations
27.363 Impact Factor

Simvastatin regulates oligodendroglial process dynamics and survival.

Glia 2007 Jan;55(2):130-43

Neuroimmunology Unit, Montreal Neurological Institute, McGill University, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/glia.20441DOI Listing
January 2007
14 Reads
21 Citations
6.031 Impact Factor

Statins in the treatment of central nervous system autoimmune disease.

J Neuroimmunol 2006 Sep 24;178(1-2):140-8. Epub 2006 Jul 24.

Department of Neurology and Program in Immunology, University of California, San Francisco, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jneuroim.2006.06.006DOI Listing
September 2006
19 Reads
14 Citations
2.470 Impact Factor

How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis.

Ann Neurol 2006 Jul;60(1):12-21

Department of Neurology and Neurological Sciences, Stanford University, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ana.20913DOI Listing
July 2006
1 Read
120 Citations
9.980 Impact Factor

Statin therapy and autoimmune disease: from protein prenylation to immunomodulation.

Nat Rev Immunol 2006 May;6(5):358-70

Department of Cell Biology, Institute of Ophthalmology, University College London, London EC1V 9EL, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nri1839DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3842637PMC
May 2006
1 Read
129 Citations
34.985 Impact Factor

A neuropeptide in immune-mediated inflammation, Y?

Trends Immunol 2006 Apr 10;27(4):164-7. Epub 2006 Mar 10.

Department of Neurology, and Program in Immunology, University of California, San Francisco, San Francisco, CA 94143-0114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.it.2006.02.003DOI Listing
April 2006
9 Reads
11 Citations
10.400 Impact Factor

Immunomodulatory synergy by combination of atorvastatin and glatiramer acetate in treatment of CNS autoimmunity.

J Clin Invest 2006 Apr 16;116(4):1037-44. Epub 2006 Mar 16.

Department of Neurology and Program in Immunology, University of California, San Francisco, San Francisco, California, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1172/JCI25805DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1401481PMC
April 2006
14 Reads
35 Citations
13.215 Impact Factor

Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin.

J Exp Med 2006 Feb 13;203(2):401-12. Epub 2006 Feb 13.

Department of Neurology and Neurological Sciences, Stanford University, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1084/jem.20051129DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2118212PMC
February 2006
3 Reads
59 Citations
12.520 Impact Factor

Evaluation of HMG-CoA reductase inhibitors for multiple sclerosis: opportunities and obstacles.

CNS Drugs 2005 ;19(10):833-41

Department of Neurology, Heinrich Heine University, Düsseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2165/00023210-200519100-00003DOI Listing
December 2005
3 Citations
5.113 Impact Factor

Drug Insight: using statins to treat neuroinflammatory disease.

Nat Clin Pract Neurol 2005 Dec;1(2):106-12

University of California San Francisco (UCSF), CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncpneuro0047DOI Listing
December 2005
6 Reads
6 Citations

Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis.

Trends Immunol 2005 Nov 8;26(11):565-71. Epub 2005 Sep 8.

Department of Neurology and Neurological Sciences, Chair Interdepartmental Program in Immunology, Stanford University, Stanford, CA 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.it.2005.08.014DOI Listing
November 2005
2 Reads
58 Citations
10.400 Impact Factor

Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis.

Neurology 2004 Dec;63(11 Suppl 5):S42-9

Multiple Sclerosis Division, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Avenue, Boston, Massachusetts 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/wnl.63.11_suppl_5.s42DOI Listing
December 2004
2 Reads
4 Citations
8.290 Impact Factor

Are statins a treatment option for multiple sclerosis?

Lancet Neurol 2004 Jun;3(6):369-71

Department of Neurology, Heinrich Heine University, Düsseldorf, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1474-4422(04)00770-7DOI Listing
June 2004
1 Read
11 Citations
21.900 Impact Factor

Mitoxantrone as a potential therapy for primary progressive multiple sclerosis.

Mult Scler 2004 Jun;10 Suppl 1:S58-61

Department of Neurology, University of California, San Francisco, 521 Parnassus Avenue, C-440, San Francisco, CA 94143-0114, USA.

View Article

Download full-text PDF

Source
June 2004
5 Reads
1 Citation
4.822 Impact Factor

Statins as potential therapeutic agents in multiple sclerosis.

Curr Neurol Neurosci Rep 2004 May;4(3):237-44

Department of Neurology, University of California-San Francisco, 521 Parnassus Avenue, C-440, San Francisco, CA 94143-0114, USA.

View Article

Download full-text PDF

Source
May 2004
9 Reads
3.060 Impact Factor

Statins and their potential targets in multiple sclerosis therapy.

Expert Opin Ther Targets 2003 Oct;7(5):613-22

Department of Neurology, University of California, San Francisco, 521 Parnassus Avenue, C-440, San Francisco, CA 94143-0114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1517/14728222.7.5.613 DOI Listing
October 2003
9 Reads
6 Citations
5.140 Impact Factor

Efficient technique for immortalization of murine microglial cells relevant for studies in murine models of multiple sclerosis.

J Neurosci Methods 2003 Sep;128(1-2):33-43

Department of Microbiology-Immunology and Interdepartmental Immunobiology Program, Northwestern University Medical School, 303 East Chicago Avenue, Chicago, IL 60611, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0165-0270(03)00145-6DOI Listing
September 2003
2 Reads
2 Citations
2.025 Impact Factor

Statins as potential therapeutic agents in neuroinflammatory disorders.

Curr Opin Neurol 2003 Jun;16(3):393-401

Department of Neurology, University of California, San Francisco, California 94143, USA.

View Article

Download full-text PDF

Source
http://pdfs.journals.lww.com/co-neurology/2003/06000/Statins
Web Search
http://www.kalbemed.com/Portals/6/komelibnew/2014/03/2010Sto
Web Search
http://dx.doi.org/10.1097/01.wco.0000073942.19076.d1DOI Listing
June 2003
2 Reads
26 Citations
5.310 Impact Factor

Diverse targets for intervention during inflammatory and neurodegenerative phases of multiple sclerosis.

Neuron 2003 Jun;38(5):685-8

Department of Neurology, University of California, San Francisco, San Francisco, CA 94143, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0896-6273(03)00326-xDOI Listing
June 2003
4 Reads
31 Citations
15.054 Impact Factor

The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease.

Nature 2002 Nov;420(6911):78-84

Department of Neurology and Neurological Sciences, Beckman Center for Molecular Medicine, Stanford University, Stanford, California 94305, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nature01158DOI Listing
November 2002
24 Reads
195 Citations
42.351 Impact Factor

Cholesterol-lowering statins possess anti-inflammatory activity that might be useful for treatment of MS.

Neurology 2002 Oct;59(7):970-1

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/wnl.59.7.970DOI Listing
October 2002
14 Citations
8.290 Impact Factor

Cutting edge: oral type I IFN-tau promotes a Th2 bias and enhances suppression of autoimmune encephalomyelitis by oral glatiramer acetate.

J Immunol 2002 Sep;169(5):2231-5

Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.169.5.2231DOI Listing
September 2002
8 Reads
12 Citations
4.922 Impact Factor

Approved and future pharmacotherapy for multiple sclerosis.

Neurologist 2002 Sep;8(5):290-301

Department of Neurology, University of California, San Francisco 94143-0114, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.nrl.0000031007.85777.18DOI Listing
September 2002
1 Read
1.080 Impact Factor

Top co-authors

Martin S Weber
Martin S Weber

University of California

28
Lawrence Steinman
Lawrence Steinman

Stanford University

26
Olaf Stuve
Olaf Stuve

University of Texas Southwestern Medical Center

21
Raymond A Sobel
Raymond A Sobel

Stanford University School of Medicine

14
Collin M Spencer
Collin M Spencer

University of California

12
Michel Varrin-Doyer
Michel Varrin-Doyer

University of California

12
Ulf Schulze-Topphoff
Ulf Schulze-Topphoff

University of California

12
Bernhard Hemmer
Bernhard Hemmer

Technische Universität München

11
Klaus Lehmann-Horn
Klaus Lehmann-Horn

Technische Universität München

10